Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer
Status:
Terminated
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
Investigators propose to study the efficacy of Bevacizumab plus systemic chemotherapy prior
to surgery in order to make a locally advanced tumor operable. Treatment is thus expected to
induce a maximum tumor shrinkage within a short period (usually 3-6 months). In addition
Bevacizumab (Avastin) is to be administered as early as possible during the disease stages.
The primary aim of this study is to evaluate the preliminary antitumor activity in terms of
pathological complete responses (pCR) of bevacizumab in combination with chemotherapy.